RU2018138028A - Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона - Google Patents
Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона Download PDFInfo
- Publication number
- RU2018138028A RU2018138028A RU2018138028A RU2018138028A RU2018138028A RU 2018138028 A RU2018138028 A RU 2018138028A RU 2018138028 A RU2018138028 A RU 2018138028A RU 2018138028 A RU2018138028 A RU 2018138028A RU 2018138028 A RU2018138028 A RU 2018138028A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- methyl
- dihydro
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 8
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical class C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 9
- 206010061218 Inflammation Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 230000004054 inflammatory process Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- MWHHJYUHCZWSLS-UHFFFAOYSA-N FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F Chemical compound FC=1C=C(C=CC1C1=C2CNC(C2=C(C=C1)C=1NC(=CN1)C)=O)NC(=O)NC1=C(C=C(C=C1F)F)F MWHHJYUHCZWSLS-UHFFFAOYSA-N 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 102000001253 Protein Kinase Human genes 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 108060006633 protein kinase Proteins 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 241000402754 Erythranthe moschata Species 0.000 claims 2
- 108091008794 FGF receptors Proteins 0.000 claims 2
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 claims 2
- 101000663003 Homo sapiens Non-receptor tyrosine-protein kinase TNK1 Proteins 0.000 claims 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 2
- 101000662997 Homo sapiens TRAF2 and NCK-interacting protein kinase Proteins 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 claims 2
- 241000772415 Neovison vison Species 0.000 claims 2
- 102100037669 Non-receptor tyrosine-protein kinase TNK1 Human genes 0.000 claims 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 2
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 102000001332 SRC Human genes 0.000 claims 2
- 102100037671 TRAF2 and NCK-interacting protein kinase Human genes 0.000 claims 2
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 claims 2
- 102100029654 Tyrosine-protein kinase Srms Human genes 0.000 claims 2
- 102100022007 Tyrosine-protein kinase receptor Tie-1 Human genes 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261746980P | 2012-12-28 | 2012-12-28 | |
| US61/746,980 | 2012-12-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015124381A Division RU2671847C2 (ru) | 2012-12-28 | 2013-12-26 | Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018138028A true RU2018138028A (ru) | 2019-03-21 |
Family
ID=51021712
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018138028A RU2018138028A (ru) | 2012-12-28 | 2013-12-26 | Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона |
| RU2015124381A RU2671847C2 (ru) | 2012-12-28 | 2013-12-26 | Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015124381A RU2671847C2 (ru) | 2012-12-28 | 2013-12-26 | Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9758508B2 (OSRAM) |
| EP (2) | EP3428161B1 (OSRAM) |
| JP (2) | JP6325573B2 (OSRAM) |
| KR (1) | KR102009163B1 (OSRAM) |
| CN (1) | CN104995184B (OSRAM) |
| AU (3) | AU2013371146C1 (OSRAM) |
| BR (1) | BR112015015477B1 (OSRAM) |
| CA (1) | CA2896711C (OSRAM) |
| DK (1) | DK2940014T3 (OSRAM) |
| ES (2) | ES2696700T3 (OSRAM) |
| MX (2) | MX2021011563A (OSRAM) |
| PL (1) | PL2940014T3 (OSRAM) |
| PT (1) | PT2940014T (OSRAM) |
| RU (2) | RU2018138028A (OSRAM) |
| WO (1) | WO2014104757A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105693720B (zh) | 2010-05-20 | 2019-01-18 | 阵列生物制药公司 | 作为trk激酶抑制剂的大环化合物 |
| MX2021011563A (es) * | 2012-12-28 | 2022-10-10 | Crystalgenomics Inc | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. |
| EP3322706B1 (en) | 2015-07-16 | 2020-11-11 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| MA46995A (fr) | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
| CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| US20180344702A1 (en) * | 2017-02-21 | 2018-12-06 | Aptose Biosciences Inc. | Methods for treating patients with hematologic malignancies |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| TW201938169A (zh) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物 |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| US20200171001A1 (en) * | 2018-11-30 | 2020-06-04 | Aptose Biosciences Inc. | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022150801A1 (en) * | 2021-01-05 | 2022-07-14 | Sumitomo Pharma Oncology, Inc. | Forms and formulations of a tyrosine kinase non-receptor 1 (tnk1) inhibitor |
| EP4301756A4 (en) * | 2021-03-05 | 2025-02-26 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND THEIR USES |
| US12071442B2 (en) | 2021-03-29 | 2024-08-27 | Nimbus Saturn, Inc. | Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4071115B2 (ja) * | 2001-04-12 | 2008-04-02 | エフ．ホフマン−ラ ロシュ アーゲー | ｍＧｌｕＲ２アンタゴニストＩＩとしてのジヒドロ−ベンゾ〔ｂ〕〔１，４〕ジアゼピン−２−オン誘導体 |
| WO2004108672A1 (en) * | 2003-06-02 | 2004-12-16 | Abbott Laboratories | Isoindolin-1-one compounds as kinase inhibitors |
| PE20061119A1 (es) * | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| CA2610446A1 (en) * | 2005-04-19 | 2006-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Nitrogen-containing heterocyclic compound |
| US20070161648A1 (en) * | 2005-10-14 | 2007-07-12 | Hughes Terry V | Substituted dihydro-isoindolones useful in treating kinase disorders |
| CA2645583A1 (en) | 2006-03-20 | 2007-09-27 | F. Hoffman-La Roche Ag | Methods of inhibiting btk and syk protein kinases |
| EP2108642A1 (en) * | 2006-10-17 | 2009-10-14 | Kyowa Hakko Kirin Co., Ltd. | Jak inhibitor |
| CA2701275C (en) | 2007-10-23 | 2016-06-21 | F. Hoffmann-La Roche Ag | Kinase inhibitors |
| WO2012014017A1 (en) | 2010-07-30 | 2012-02-02 | Poly Medicure Limited | Catheter introducer |
| WO2012047017A2 (ko) * | 2010-10-05 | 2012-04-12 | 크리스탈지노믹스(주) | 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물 |
| MX2021011563A (es) | 2012-12-28 | 2022-10-10 | Crystalgenomics Inc | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. |
| US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
-
2013
- 2013-12-26 MX MX2021011563A patent/MX2021011563A/es unknown
- 2013-12-26 BR BR112015015477-8A patent/BR112015015477B1/pt active IP Right Grant
- 2013-12-26 RU RU2018138028A patent/RU2018138028A/ru unknown
- 2013-12-26 ES ES13867650T patent/ES2696700T3/es active Active
- 2013-12-26 US US14/655,954 patent/US9758508B2/en active Active
- 2013-12-26 ES ES18190153T patent/ES2929906T3/es active Active
- 2013-12-26 PT PT13867650T patent/PT2940014T/pt unknown
- 2013-12-26 EP EP18190153.9A patent/EP3428161B1/en active Active
- 2013-12-26 KR KR1020157018342A patent/KR102009163B1/ko active Active
- 2013-12-26 WO PCT/KR2013/012204 patent/WO2014104757A1/ko not_active Ceased
- 2013-12-26 RU RU2015124381A patent/RU2671847C2/ru active
- 2013-12-26 MX MX2015008396A patent/MX386542B/es unknown
- 2013-12-26 PL PL13867650T patent/PL2940014T3/pl unknown
- 2013-12-26 EP EP13867650.7A patent/EP2940014B1/en active Active
- 2013-12-26 AU AU2013371146A patent/AU2013371146C1/en active Active
- 2013-12-26 CN CN201380068623.6A patent/CN104995184B/zh active Active
- 2013-12-26 DK DK13867650.7T patent/DK2940014T3/en active
- 2013-12-26 CA CA2896711A patent/CA2896711C/en active Active
- 2013-12-26 JP JP2015550315A patent/JP6325573B2/ja active Active
-
2017
- 2017-08-30 US US15/691,432 patent/US10604508B2/en active Active
-
2018
- 2018-04-12 JP JP2018076877A patent/JP6596537B2/ja active Active
- 2018-08-10 AU AU2018214134A patent/AU2018214134B2/en active Active
-
2020
- 2020-02-14 US US16/791,753 patent/US11230539B2/en active Active
- 2020-02-27 AU AU2020201431A patent/AU2020201431B2/en active Active
-
2022
- 2022-07-22 US US17/871,458 patent/US20220380346A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018138028A (ru) | Производные 2,3-дигидро-изоиндол-1-она и способы их применения в качестве ингибиторов тирозинкиназы брутона | |
| ES2532764T3 (es) | Inhibidores de pirazol p38 MAP quinasa | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| EA200870373A1 (ru) | Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ | |
| EA201491671A1 (ru) | Гетероциклильные соединения | |
| MX392440B (es) | Inhibidores de tirosina quinasa de bazo (syk). | |
| UA99141C2 (ru) | Замещенные производные индазола, активные в качестве ингибиторов киназы | |
| EA201992270A3 (ru) | 4-имидазопиридазин-1-ил-бензамиды и 4-имидазотриазин-1-ил-бензамиды в качестве btk-ингибиторов | |
| AR092045A1 (es) | Combinaciones farmaceuticas | |
| ECSP13012852A (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a. | |
| BR112013029862A2 (pt) | derivados de piridin-2 (1h)-ona úteis como medicamentos para o tratamento de distúrbios mieloproliferativos, rejeição a transplante, doenças imunomediadas e inflamatórias | |
| EA201490647A1 (ru) | Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции | |
| CL2011000306A1 (es) | Compuestos derivados de di-alquilamida del acido 7-ciclopentil-2-[5-(piperidin o piperazin sustituido)-piridin-2-il amino]-7h-pirrolo-[2,3-d]-pirimidin-6-carboxilico, inhibidores de cdk4; composicion farmaceutica; y su uso para el tratamiento del cancer o la inflamacion. | |
| AR060631A1 (es) | Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k) | |
| EA201591051A1 (ru) | Ингибиторы erk и варианты их применения | |
| EA201592287A1 (ru) | Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения | |
| MX2015014387A (es) | Quinazolinas y azaquinazolinas como inhibidores duales de vias ras/raf/mek/erk y pi3k/akt/pten/mtor. | |
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| EA201500050A1 (ru) | Бифтордиоксалан-амино-бензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс | |
| EA201070929A1 (ru) | ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ | |
| ATE534292T1 (de) | Spiroverbindungen und anwendungsverfahren dafür | |
| EA201590183A1 (ru) | Производные азаиндола, выступающие в качестве ингибиторов pi3k | |
| EA201490630A1 (ru) | 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы | |
| EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
| RU2013127655A (ru) | Фармацевтическая комбинация паклитаксела и ингибитора cdk |